The Use of Long-Acting Injectable Antipsychotics in Schizophrenia: Evaluating the Evidence
The DOI matches its Crossref record, with a small difference in title or year; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Long-acting injectable antipsychotics (LAIs) are among the most effective treatments in psychiatry, yet they remain underutilized in clinical practice. Although LAIs are typically used to maintain treatment adherence in patients with chronic schizophrenia, recent research has suggested that they may also provide an effective treatment strategy for patients with early-phase or first-episode disease. In October 2015, a group of 8 experts on the management of schizophrenia and LAIs met to evaluate the evidence surrounding the efficacy, safety, and cost-effectiveness of LAIs and to develop practical recommendations regarding the clinical use, education, and unmet needs related to LAIs. Participants were also asked to rate the importance of several patient characteristics when choosing an LAI versus an oral antipsychotic, from the perspectives of 4 different stakeholder groups: patients, health care professionals, families, and payers. The evidence review demonstrated that LAIs are superior to placebo for acute and maintenance treatment of schizophrenia and, in general, appear to be similar to one another in terms of schizophrenia relapse prevention. Study design impacts the demonstrated efficacy of LAIs versus oral antipsychotics, but recent database and randomized controlled studies favor the use of LAIs in early-phase schizophrenia patients. LAIs vary considerably in their propensity to cause certain adverse effects, including weight gain, metabolic effects, extrapyramidal symptoms, and prolactin elevation, and these differences can be used to help guide LAI selection. Some studies, but not all, have demonstrated significant reductions in health care utilization or overall costs with LAIs. The expert panel identified several barriers to LAI use in current practice, including clinician lack of knowledge, negative attitudes about LAIs, and resource and cost issues. The participants also identified a number of additional factors that should be considered when weighing the use of LAI therapy, including medication adherence, relapse risk and severity, cognitive impairment, ease of use, substance misuse, access and cost, stigma, social support, patient autonomy, control over medication dosing, fear of needles, and the potential for patient harm due to relapses and associated loss of functioning. This evidence review, discussion, and summary recommendations may help clinicians, patients, families, payers, and other stakeholders to better characterize the role of LAIs in the treatment of schizophrenia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition to the benefits of reduced treatment gaps with LAI versus oral antipsychotics, studies, particularly those in real-world samples, have demonstrated reduced psychopathology, relapses, hospitalizations, and mortality risk with LAI formulations [98–104].”
From Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview (2021) · cites this paper as [100]
In the citing paper
“Longacting injectable antipsychotics can enhance adherence, 10 but surveys of physician attitudes about LAIs show that they consider LAIs primarily for patients who have already had repeated hospitalizations and relapses.11”
From Effect of Long-Acting Injectable Antipsychotics vs Usual Care on Time to First Hospitalization in Early-Phase Schizophrenia: A Randomized Clinical Trial (2020) · cites this paper as [10]
In the citing paper
“Currently, a number of studies have proven the effectiveness, safety and tolerability of LAIs [25]”
From The role of shared decision-making in improving adherence to pharmacological treatments in patients with schizophrenia: A clinical review (2020) · cites this paper as [25]
Citations
Cites
The publisher hasn’t deposited this paper’s reference list.
Cited by
Barnes, T. R., Drake, R., Paton, C., Cooper, S. J., Deakin, B., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 606
Self-citationImproving outcomes of first‐episode psychosis: an overview
Fusar‐Poli, P., McGorry, P. D., & Kane, J. M. (2017) · World Psychiatry · doi:10.1002/wps.20446 · Cited by 575
Self-citationThe COVID-19 Global Pandemic: Implications for People With Schizophrenia and Related Disorders
Kozloff, N., Mulsant, B. H., Stergiopoulos, V., & Voineskos, A. N. (2020) · Schizophrenia Bulletin · doi:10.1093/schbul/sbaa051 · Cited by 379
Kane, J. M., Schooler, N. R., Marcy, P., Correll, C. U., Achtyes, E. D., Gibbons, R. D., & Robinson, D. G. (2020) · JAMA psychiatry · doi:10.1001/jamapsychiatry.2020.2076 · Cited by 208
Self-citationCorrell, C. U., Kim, E., Sliwa, J. K., Hamm, W., Gopal, S., Mathews, M., Venkatasubramanian, R., & Saklad, S. R. (2021) · CNS Drugs · doi:10.1007/s40263-020-00779-5 · Cited by 205
Self-citationGreene, M., Yan, T., Chang, E., Hartry, A., Touya, M., & Broder, M. S. (2018) · Journal of Medical Economics · doi:10.1080/13696998.2017.1379412 · Cited by 200
Patel, C., Emond, B., Lafeuille, M.-H., Côté-Sergent, A., Lefebvre, P., Tandon, N., & El Khoury, A. C. (2020) · Drugs - Real World Outcomes · doi:10.1007/s40801-019-00172-9 · Cited by 185
Correll, C. U., Martin, A. L., Patel, C. A., Benson, C. J., Goulding, R., Sliwa, J. K., Joshi, K., Schiller, E., & Kim, E. (2022) · Schizophrenia · doi:10.1038/s41537-021-00192-x · Cited by 182
Self-citationPacchiarotti, I., Tiihonen, J., Kotzalidis, G. D., Verdolini, N., Murru, A., Goikolea, J. M., Valentí, M., Aedo, A., & Vieta, E. (2019) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2019.02.003 · Cited by 128
Krogmann, A., Peters, L., von Hardenberg, L., Bödeker, K., Nöhles, V. B., & Correll, C. U. (2019) · CNS Spectrums · doi:10.1017/s109285291900124x · Cited by 126
Self-citationFiorillo, A., Barlati, S., Bellomo, A., Corrivetti, G., Nicolò, G., Sampogna, G., Stanga, V., Veltro, F., Maina, G., & Vita, A. (2020) · Annals of General Psychiatry · doi:10.1186/s12991-020-00293-4 · Cited by 110
Ostuzzi, G., Bertolini, F., Giovane, C. D., Tedeschi, F., Bovo, C., Gastaldon, C., Nosè, M., Ogheri, F., Papola, D., Purgato, M., et al. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20071120 · Cited by 93
Self-citationA safety evaluation of aripiprazole in the treatment of schizophrenia
Preda, A., & Shapiro, B. B. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1832990 · Cited by 86
Kane, J. M., McEvoy, J. P., Correll, C. U., & Llorca, P. (2021) · CNS Drugs · doi:10.1007/s40263-021-00861-6 · Cited by 94
Self-citationClozapine resistant schizophrenia: Newer avenues of management
Chakrabarti, S. (2021) · World Journal of Psychiatry · doi:10.5498/wjp.v11.i8.429 · Cited by 90
Højlund, M., Kemp, A. F., Haddad, P. M., Neill, J. C., & Correll, C. U. (2021) · The Lancet Psychiatry · doi:10.1016/s2215-0366(21)00078-x · Cited by 75
Self-citationThe Use of Long-Acting Injectable Antipsychotics in Schizophrenia
Miyamoto, S., & Fleischhacker, W. W. (2017) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-017-0115-z · Cited by 82
Lee, W. Y., Asadujjaman, M., & Jee, J. (2019) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-019-00449-9 · Cited by 69
Najarian, D. M., Sanga, P., Wang, S., Lim, P., Singh, A., Robertson, M. J., Cohen, K., Schotte, A., Milz, R., Venkatasubramanian, R., et al. (2021) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyab071 · Cited by 74
Pietrini, F., Albert, U., Ballerini, A., Calò, P., Maina, G., Pinna, F., Vaggi, M., Boggian, I., Fontana, M., Moro, C. G., et al. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s199048 · Cited by 70
Long-Acting Injectable Second-Generation Antipsychotics: An Update and Comparison Between Agents
Jann, M. W., & Penzak, S. R. (2018) · CNS Drugs · doi:10.1007/s40263-018-0508-6 · Cited by 63
Guinart, D., Misawa, F., Rubio, J. M., Pereira, J., de Filippis, R., Gastaldon, C., Kane, J. M., & Correll, C. U. (2021) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13359 · Cited by 69
Self-citationNayan, M. U., Sillman, B., Hasan, M., Deodhar, S., Das, S., Sultana, A., Le, N. T. H., Soriano, V., Edagwa, B., & Gendelman, H. E. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115009 · Cited by 64
Lindenmayer, J., Glick, I. D., Talreja, H., & Underriner, M. (2020) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001225 · Cited by 61
Lin, D., Kim, H., Wada, K., Aboumrad, M., Powell, E. I., Zwain, G., Benson, C. J., & Near, A. M. (2022) · BMC Psychiatry · doi:10.1186/s12888-022-04022-x · Cited by 65
Rubio, J. M., & Kane, J. M. (2019) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13111 · Cited by 62
Self-citationLong-acting antipsychotics in the treatment of schizophrenia: opportunities and challenges
Haddad, P. M., & Correll, C. U. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2181073 · Cited by 63
Self-citationYan, T., Greene, M., Chang, E. Y., Hartry, A., Touya, M., & Broder, M. S. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0785-y · Cited by 56
Long-acting injectable antipsychotics for early psychosis: A comprehensive systematic review
Lian, L., Kim, D. D., Procyshyn, R. M., Cázares, D., Honer, W. G., & Barr, A. M. (2022) · PLoS ONE · doi:10.1371/journal.pone.0267808 · Cited by 59
Variation in Psychotropic Medication Prescription for Adults With Schizophrenia in the United States
Bareis, N., Olfson, M., Wall, M. M., & Stroup, T. S. (2021) · Psychiatric Services · doi:10.1176/appi.ps.202000932 · Cited by 52
Self-citationLian, L., Kim, D. D., Procyshyn, R. M., Fredrikson, D. H., Cázares, D., Honer, W. G., & Barr, A. M. (2021) · Early Intervention in Psychiatry · doi:10.1111/eip.13202 · Cited by 53
Mohr, P., Knytl, P., Voráčková, V., Bravermanová, A., & Melicher, T. (2017) · International Journal of Clinical Practice · doi:10.1111/ijcp.12997 · Cited by 55
Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia
Mathews, M., Gopal, S., Nuamah, I. F., Hargarter, L., Savitz, A. J., Kim, E., Tan, W., Soares, B. G., & Correll, C. U. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s197225 · Cited by 46
Self-citationPsychosis breakthrough on antipsychotic maintenance: results from a nationwide study
Rubio, J. M., Taipale, H., Correll, C. U., Tanskanen, A., Kane, J. M., & Tiihonen, J. (2020) · Psychological Medicine · doi:10.1017/s0033291719001296 · Cited by 45
“This allowed us to study the phenomenon during treatment episodes with a more conservative estimate of treatment continuity given the assured exposure and pharmacokinetic properties of LAIs (Correll et al., 2016).”
BackgroundSelf-citationSajatovic, M., Ross, R., Legacy, S. N., Correll, C. U., Kane, J. M., DiBiasi, F., Fitzgerald, H., & Byerly, M. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s167394 · Cited by 44
Self-citationGuinart, D., Taipale, H. T., Rubio, J. M., Tanskanen, A. J., Correll, C. U., Tiihonen, J., & Kane, J. M. (2021) · Schizophrenia Bulletin · doi:10.1093/schbul/sbab062 · Cited by 54
Self-citationLorenzo, R. D., Ferri, P., Cameli, M., Rovesti, S., & Piemonte, C. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s189245 · Cited by 48
Wu, C.-S., Luedtke, A. R., Sadikova, E., Tsai, H.-J., Liao, S.-C., Liu, C.-C., Gau, S. S.-F., VanderWeele, T. J., & Kessler, R. C. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.21660 · Cited by 42
Emsley, R., Asmal, L., Rubio, J. M., Correll, C. U., & Kane, J. M. (2020) · Schizophrenia Research · doi:10.1016/j.schres.2019.11.025 · Cited by 41
Self-citationArango, C., Baeza, I., Bernardo, M., Cañas, F., de Dios, C., Díaz‐Marsá, M., García‐Portilla, M. P., Gutiérrez-Rojas, L., Olivares, J. M., Rico‐Villademoros, F., et al. (2018) · Revista de Psiquiatría y Salud Mental · doi:10.1016/j.rpsm.2018.03.006 · Cited by 53
Sajatovic, M., ROSS, R. W., Legacy, S. N., Byerly, M., Kane, J. M., DiBiasi, F., Fitzgerald, H. M., & Correll, C. U. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s167485 · Cited by 46
Self-citationStip, É., & Lachaîne, J. (2018) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125318782694 · Cited by 40
Abdel‐Baki, A., Thibault, D., Medrano, S., Stip, É., Ladouceur, M., Tahir, M. R., & Potvin, S. (2019) · Early Intervention in Psychiatry · doi:10.1111/eip.12826 · Cited by 47
Guan, I., Kirwan, N., Beder, M., Levy, M., & Law, S. (2020) · Community Mental Health Journal · doi:10.1007/s10597-020-00710-8 · Cited by 40
Lin, C., Chen, F.-C., Chan, H., & Hsu, C. (2019) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz035 · Cited by 40
Correll, C. U., Litman, R. E., Filts, Y., Llaudó, J., Naber, D., Torres, F., & Martínez, J. (2020) · Schizophrenia · doi:10.1038/s41537-020-00127-y · Cited by 41
Self-citationMunday, J., Greene, M., Chang, E. Y., Hartry, A., Yan, T., & Broder, M. S. (2019) · Current Medical Research and Opinion · doi:10.1080/03007995.2019.1571295 · Cited by 40
Current and emerging long-acting antipsychotics for the treatment of schizophrenia
de Filippis, R., Fazio, P. D., Gaetano, R., Steardo, L., Cedro, C., Bruno, A., Zoccali, R. A., & Muscatello, M. R. A. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1910674 · Cited by 47
Coles, A. S., Knezevic, D., George, T. P., Correll, C. U., Kane, J. M., & Castle, D. J. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.808002 · Cited by 46
Self-citationSariaslan, A., Leucht, S., Zetterqvist, J., Lichtenstein, P., & Fazel, S. (2021) · Psychological Medicine · doi:10.1017/s0033291721000556 · Cited by 46
Lin, C., Chen, F.-C., Chan, H., & Hsu, C. (2019) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2019.08.005 · Cited by 38
Højlund, M., & Correll, C. U. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2228686 · Cited by 40
Self-citationKane, J. M., Harary, E., Eshet, R., Tohami, O., Weiser, M., Leucht, S., Wagner, A. M., Sharon, N. A., Davis, G. L., Suett, M., et al. (2023) · The Lancet Psychiatry · doi:10.1016/s2215-0366(23)00288-2 · Cited by 36
Self-citationOlagunju, A. T., Clark, S. R., & Baune, B. T. (2019) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867419837358 · Cited by 37
Citrome, L. (2017) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2017.1371014 · Cited by 35
Self-citationThe ‘Parma‐Early Psychosis’ programme: Characterization of help‐seekers with first episode psychosis
Landi, G., Leuci, E., Quattrone, E., Azzali, S., Pellegrini, C., Pellegrini, P., & Pelizza, L. (2020) · Early Intervention in Psychiatry · doi:10.1111/eip.12968 · Cited by 35
Goldstone, L. W., DiPaula, B. A., Werremeyer, A. B., Botts, S. R., Hepburn, B. M., Liu, H. Y., Duckworth, K., Young, A. S., & Kelly, D. L. (2021) · Psychiatric Services · doi:10.1176/appi.ps.202000066 · Cited by 38
Using Long-acting Injectable Antipsychotics to Enhance the Potential for Recovery in Schizophrenia
Correll, C. U., & Lauriello, J. (2020) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.ms19053ah5c · Cited by 36
Self-citationSchöttle, D., Janetzky, W., Luedecke, D., Beck, E., Correll, C. U., & Wiedemann, K. (2018) · BMC Psychiatry · doi:10.1186/s12888-018-1946-x · Cited by 32
Self-citationPharmacological treatment of violence in schizophrenia
Strassnig, M., Nascimento, V. M., Deckler, E., & Harvey, P. D. (2019) · CNS Spectrums · doi:10.1017/s1092852919001226 · Cited by 30
Miranda, J. J. F., Díaz-Fernández, S., Berardis, D. D., & Lopez-Munoz, F. J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10071408 · Cited by 31
Martin, A. L., Bessonova, L., Hughes, R. L., Doane, M. J., O’Sullivan, A. K., Snook, K., Cichewicz, A. B., Weiden, P. J., & Harvey, P. D. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02232-z · Cited by 35
Wang, D., Schneider-Thoma, J., Siafis, S., Burschinski, A., Dong, S., Wu, H., Zhu, Y., Davis, J. M., Priller, J., & Leucht, S. (2024) · Schizophrenia Bulletin · doi:10.1093/schbul/sbad089 · Cited by 29
Vita, G., Tavella, A., Ostuzzi, G., Tedeschi, F., Prisco, M. D., Segarra, R., Solmi, M., Barbui, C., & Correll, C. U. (2024) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253241257062 · Cited by 35
Self-citationCitrome, L., Belcher, E. D., Stacy, S., Suett, M., Mychaskiw, M. A., & Salinas, G. D. (2022) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s326299 · Cited by 29
Self-citationDíaz-Fernández, S., Frías-Ortiz, D. F., & Miranda, J. J. F. (2019) · Psychiatry Research · doi:10.1016/j.psychres.2019.112479 · Cited by 33
Understanding healthcare burden and treatment patterns among young adults with schizophrenia
Huang, A., Amos, T. B., Joshi, K., Wang, L., & Nash, A. I. (2018) · Journal of Medical Economics · doi:10.1080/13696998.2018.1500370 · Cited by 29
Arango, C., Fagiolini, A. M., Gorwood, P. A. P. M., Kane, J. M., Diaz-Mendoza, S., Sahota, N., & Correll, C. U. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-04928-0 · Cited by 29
Self-citationCorrell, C. U., Sliwa, J. K., Najarian, D. M., & Saklad, S. R. (2019) · CNS Spectrums · doi:10.1017/s1092852918001098 · Cited by 27
Self-citationCorrell, C. U., Jain, R., Meyer, J. M., Periclou, A. P., Carrothers, T. J., Barabássy, Á., Patel, M., & Earley, W. R. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s210340 · Cited by 33
Self-citationCalabrese, J. R., Sanchez, R., Jin, N., Amatniek, J. C., Cox, K., Johnson, B. R., Perry, P. P., Hertel, P., Such, P., McQuade, R. D., et al. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.10.035 · Cited by 29
Reinstein, S. A., Cosgrove, J., Malekshahi, T., & Deligiannidis, K. M. (2020) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.20ac13597 · Cited by 27
Correll, C. U., Benson, C. J., Émond, B., Patel, C. A., Lafeuille, M., Lin, D., Morrison, L., Ghelerter, I., Lefèbvre, P., & Mavros, P. (2023) · Schizophrenia · doi:10.1038/s41537-023-00334-3 · Cited by 27
Self-citationPeters, L., Krogmann, A., von Hardenberg, L., Bödeker, K., Nöhles, V. B., & Correll, C. U. (2019) · Current Psychiatry Reports · doi:10.1007/s11920-019-1114-0 · Cited by 27
Self-citationMahlich, J., Olbrich, K., Wilk, A., Wimmer, A., & Wolff‐Menzler, C. (2020) · Clinical Drug Investigation · doi:10.1007/s40261-020-00990-8 · Cited by 30
Medrano, S., Abdel‐Baki, A., Stip, É., & Potvin, S. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4577 · Cited by 27
Anta, L., Llaudó, J., Ayani, I., Martínez, J., Litman, R. E., & Gutierro, I. (2017) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000203 · Cited by 24
Reymann, S., Schoretsanitis, G., Egger, S., Mohonko, A., Kirschner, M., Vetter, S., Homan, P., Seifritz, E., & Burrer, A. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12030441 · Cited by 23
Filts, Y., Litman, R. E., Martínez, J., Anta, L., Naber, D., & Correll, C. U. (2021) · Schizophrenia Research · doi:10.1016/j.schres.2021.11.030 · Cited by 25
Self-citationRisperidone ISM as a New Option in the Clinical Management of Schizophrenia: A Narrative Review
Álamo, C. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02299-8 · Cited by 25
Riboldi, I., Cavaleri, D., Capogrosso, C. A., Crocamo, C., Bartoli, F., & Carrà, G. (2022) · Psychology Research and Behavior Management · doi:10.2147/prbm.s371991 · Cited by 31
Legrand, G., Guiguet‐Auclair, C., Viennet, H., Auméran, C., Reynaud, D., Badrikian, L., & Debost‐Legrand, A. (2019) · Journal of Clinical Nursing · doi:10.1111/jocn.14909 · Cited by 21
Edwards, G. G., Ochoa, A. M., Castillo, E. G., Goodman‐Meza, D., Kalofonos, I., Landovitz, R. J., Leibowitz, A. A., Pulsipher, C., Sayed, E. E., SHOPTAW, S. J., et al. (2022) · AIDS and Behavior · doi:10.1007/s10461-022-03817-z · Cited by 25
Pae, C., Wang, S., Han, C., Bahk, W., Lee, S.-J., Patkar, A. A., Masand, P. S., Serretti, A., & Emsley, R. A. (2017) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000177 · Cited by 25
Nielsen, R. E., Hessellund, K. B., Valentin, J. B., & Licht, R. W. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2018.07.020 · Cited by 22
Tveito, M., Smith, R. L., Molden, E., Haslemo, T., Refsum, H., Hartberg, C. B., Correll, C. U., & Høiseth, G. (2018) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000961 · Cited by 21
Self-citationAripiprazole Lauroxil NanoCrystal®Dispersion Technology (Aristada Initio®)
Ehret, M. J., Davis, E., Luttrell, S. E., & Clark, C. (2018) · Clinical Schizophrenia & Related Psychoses · doi:10.3371/csrp.ehda071918 · Cited by 22
Magliocco, F., de Filippis, R., Aloi, M., Staltari, F. A., Gaetano, R., Segura‐Garcìa, C., & Fazio, P. D. (2020) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2020.1737134 · Cited by 22
Taipale, H. T., Tanskanen, A. J., Luykx, J. J., Solmi, M., Leucht, S., Correll, C. U., & Tiihonen, J. (2022) · Schizophrenia Bulletin · doi:10.1093/schbul/sbac039 · Cited by 22
Self-citationSolmi, M., Lähteenvuo, M., Correll, C. U., Tanskanen, A. J., Tiihonen, J., & Taipale, H. T. (2022) · Schizophrenia Bulletin · doi:10.1093/schbul/sbac152 · Cited by 24
Self-citationBehavioral Health Care Delivery Through Street Medicine Programs in California
Su, K. Y., Feldman, B. J., Feldman, C. T., Saluja, S., Kogan, A. C., & Cousineau, M. R. (2023) · Community Mental Health Journal · doi:10.1007/s10597-023-01169-z · Cited by 23
Poloni, N., Ielmini, M., Caselli, I., Lucca, G., Gasparini, A., Gasparini, A., Lorenzoli, G., & Callegari, C. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4590 · Cited by 27
Abdel‐Baki, A., Medrano, S., Maranda, C., Ladouceur, M., Tahir, M. R., Stip, É., & Potvin, S. (2020) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000310 · Cited by 23
Schöttle, D., Janetzky, W., Luedecke, D., Beck, E., Correll, C. U., & Wiedemann, K. (2020) · BMC Psychiatry · doi:10.1186/s12888-020-02488-1 · Cited by 21
Self-citationZhu, J., Chen, Y., Lu, W., Huang, Q., Li, B., Xu, Y., Xi, R., & Jin, L. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.770276 · Cited by 19
Najarian, D. M., Turkoz, I., Knight, R. K., Galderisi, S., Lamaison, H. F., Zalitacz, P., Aravind, S., & Richarz, U. (2023) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyad028 · Cited by 24
Long-acting injectable HIV therapies: the next frontier
Thornhill, J. P., & Orkin, C. M. (2020) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000701 · Cited by 23
Tveito, M., Molden, E., Høiseth, G., Correll, C. U., & Smith, R. L. (2019) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-019-02768-0 · Cited by 21
Self-citationWalling, D. P., Hassman, H. A., Anta, L., D., L. O., Ayani, I., Martínez, J., & Gutierro, I. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s332026 · Cited by 18
Hsieh, W. L., Yeh, S. T., Liu, W., Li, I. H., Lee, S. K., & Chien, W. T. (2022) · Patient Preference and Adherence · doi:10.2147/ppa.s351848 · Cited by 30
Metadata
- Authors
- Correll, C. U., Citrome, L., Haddad, P. M., Lauriello, J., Olfson, M., Calloway, S. M., & Kane, J. M.
- Affiliations
- Hofstra University (US)
- New York Medical College (US)
- University of Manchester (GB)
- University of Missouri (US)
- Columbia University (US)
- Missouri Department of Social Services (US)
- Northwell Health (US)
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2016-09-30
- Volume
- 77
- Issue
- Suppl 3
- Pages
- 1-24
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2527103551
- Cited by
- 372
- References
- 0
- Citations by year
- 2026: 28 · 2025: 36 · 2024: 37 · 2023: 54 · 2022: 40 · 2021: 50 · 2020: 36 · 2019: 49 · 2018: 22 · 2017: 20
- FWCI
- 27.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
- Social Sciences › Psychology › Clinical Psychology › Family Caregiving in Mental Illness
- Keywords
- long-acting injectable antipsychotics, schizophrenia, first-episode schizophrenia, medication adherence, relapse prevention, cost-effectiveness, adverse effects, weight gain, metabolic effects, extrapyramidal symptoms, prolactin elevation, stakeholder perspectives, clinical guidelines
- MeSH terms
- Chronic Disease, Cost-Benefit Analysis, Delayed-Action Preparations, Humans, Injections, Intramuscular, Mental Health Services, Schizophrenia, Schizophrenic Psychology, Antipsychotic Agents, Utilization Review, Randomized Controlled Trials as Topic, Treatment Outcome, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.